• Necrosulfonamide in Necroptosis Research

  2026-10-10

  Necrosulfonamide (NSA) is described as an MLKL-directed inhibitor for studying necroptotic membrane failure. This overview places the compound in the context of a 2025 study linking hyperhomocysteinemia, peroxynitrite, calcium dysregulation and cardiac microvascular necroptosis, while distinguishing supplier-reported pharmacology from independently demonstrated disease-model evidence.

• Cediranib (AZD2171): Beyond Simple Viability

  2026-10-09

  A translational framework for interpreting Cediranib and AZD2171 through angiogenic signaling, response metrics, evidence boundaries, and next-generation cancer research strategy.

• Recombinant Human FGF-19 Product Overview

  2026-10-09

  APExBIO describes Recombinant Human FGF-19 (SKU P1050) as an E. coli-expressed, tag-free, lyophilized FGF-19 protein intended for conceptual research involving FGFR4 binding, endocrine signaling, and metabolic regulation. The reported specifications and activity results are supplier-provided; no matched paper evidence was supplied.

• NAT1–ENO1–Lactate Axis in Colorectal Cancer

  2026-10-08

  A 2026 MedComm study links NAT1 loss to increased ENO1 activity, lactate production, TRAF6 activation, and PD-L1 stabilization in colorectal cancer. The work provides a preclinical framework connecting tumor glycolysis with immune checkpoint regulation, while its biomarker and therapeutic implications still require clinical validation.

• MRSA Extracellular Vesicles and OSCC Proliferation

  2026-10-08

  A 2026 study reports that extracellular vesicles released by methicillin-resistant Staphylococcus aureus can promote oral squamous cell carcinoma proliferation through an IL-8–CXCR1 signaling axis. The work expands Staphylococcus aureus infection research beyond infection control by examining antibiotic-resistant bacteria as active participants in tumor–microbe interactions, while remaining limited by its model systems and the need for independent validation.

• MCL-1 Dependence in Breast Cancer: Study Evidence

  2026-10-07

  Campbell and colleagues show that established breast tumours depend on MCL-1 primarily through its canonical anti-apoptotic activity, demonstrated by genetic deletion, pharmacological inhibition, and BAX/BAK dependency. The findings strengthen the rationale for studying MCL-1-directed BH3 mimetics in breast cancer while defining important limits around model context, pharmacological specificity, and clinical translation.

• MVC Exploits RhoA/ROCK1/MLC2 to Disrupt Tight Junctions

  2026-10-07

  Ren and colleagues identify a previously uncharacterized connection between MVC VP2, ROCK1, and the RhoA/ROCK1/MLC2 pathway in canine cells. Their findings support a model in which actomyosin contraction redistributes Occludin, weakens tight-junction organization, and promotes MVC infection, while also defining important limits for interpreting pathway-inhibitor evidence.

• CYR61, Migrasomes, and Irradiated BMSC Repair

  2026-10-06

  A 2025 study links CYR61, integrin αvβ3–ERK signaling, and migrasomes to the recovery of migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells. The findings offer a mechanistic framework for osteoradionecrosis research, while remaining limited to an in vitro cellular model and requiring validation in more complex systems.

• Bismuth Subsalicylate: Readouts That Matter

  2026-10-06

  Bismuth Subsalicylate research is strongest when prostaglandin biology, inflammatory phenotypes, and cell-state readouts are interpreted together. This article develops an evidence-centered framework using annexin V research to clarify what membrane changes can—and cannot—show in gastrointestinal disorder studies.

• NFIA Coordinates Bone Formation and Resorption

  2026-10-05

  A 2026 Genes & Diseases study identifies nuclear factor I/A (NFIA) as a context-dependent regulator of bone homeostasis in mesenchymal stem and progenitor cells. By controlling stromal RANKL and SFRP1 expression, NFIA restrains osteoclast support while also limiting osteoblast differentiation, with loss of resorption control dominating the resulting bone-loss phenotype.

• PBS (Phosphate-Buffered Saline) Overview

  2026-10-05

  APExBIO PBS, SKU K2818, is described as a sterile, ready-to-use phosphate-buffered saline solution for routine laboratory handling. No matched paper evidence was provided, so performance and assay compatibility cannot be independently assessed.

• Prion Self-Assembly and Adaptive Mutagenesis

  2026-10-04

  A 2026 Cell study reports that prion-based protein self-assembly can reversibly and heritably tune DNA mutagenesis in yeast, reshaping adaptation under strong selection. The work links protein-state inheritance with genome stability and drug-resistance trajectories while highlighting important limits on extrapolation to clinical biology.

• RG108: Evidence, Mechanism, Scope, and Limits

  2026-10-03

  RG108 is described by APExBIO as a small-molecule DNA methyltransferase inhibitor, but the supplied evidence is mainly a product description rather than an independent, peer-reviewed evaluation. This overview explains what the mechanism may support, why biochemical potency does not establish cellular or clinical efficacy, and why findings from a separate 6-thioguanine study should not be attributed to RG108.

• Dual-Action Inhibitors Reprogram p38α Dephosphorylation

  2026-10-02

  The reference study shows that selected kinase inhibitors can do more than block p38α catalysis: they also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-accessible activation-loop conformation. This structure-guided mechanism provides a framework for designing inhibitors that combine active-site blockade with faster kinase deactivation, while leaving disease-model translation to future studies.

• CUDC-907: Practical PI3K/HDAC Workflow Guide

  2026-10-01

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, chromatin-associated responses, cell-cycle distribution, and apoptosis. This dossier-based guide provides starting conditions and QC checks, while emphasizing that the compound is for scientific research only and is not validated for diagnosis, treatment, or clinical decision-making.

8101 records 1/541 page Next 12345 下5页 Last page